Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabinoids, particularly cannabidiol (CBD), have been investigated for their potential to support the treatment of substance use disorders and addictions. Scientific interest in this area has grown in recent years, but the evidence remains preliminary and limited. Some preclinical studies and small-scale human trials suggest that CBD may help reduce cravings and anxiety associated with withdrawal from substances such as opioids, tobacco, and alcohol. For example, a 2019 randomized controlled trial found that CBD reduced cue-induced craving and anxiety in individuals with heroin use disorder. Other studies have explored the potential of cannabinoids to modulate the brain’s reward circuitry, possibly reducing the reinforcing effects of addictive substances. However, the overall quality and quantity of evidence are limited. Most studies are small, short-term, and have methodological limitations. There is also concern about the psychoactive properties and abuse potential of some cannabinoids, particularly THC, which can complicate their use in addiction treatment. Major medical organizations have not yet endorsed cannabinoids as standard therapy for addiction. Thus, while there is scientific interest and some preliminary evidence, cannabinoids are not currently considered a validated or widely accepted treatment for addiction, and more robust research is needed to clarify their role.

More about Cannabinoids
More about Addictions (general remedies for)

Other ingredients used for Addictions (general remedies for)

Other health conditions supported by Cannabinoids

Products containing Cannabinoids